TI
CMTA

Trexquant Investment’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Trexquant Investment’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,275
Closed -$126K – 1449
2018
Q3 		$126K Buy
+11,275
New +$119K 0.01% 882

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Trexquant Investment's CMTA Position: Q4 2018 in Review

Trexquant Investment sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q4 2018, closing a stake of 11,275 shares — an estimated $126K sold.

Trexquant Investment first reported a position in CMTA in Q3 2018 and held it in 1 quarter. The position peaked at $126K in Q3 2018. 31 funds tracked by Wall St. Rank hold CMTA as of Q4 2018.

  • Trexquant Investment reported no remaining Clementia Pharmaceuticals Inc. position as of Q4 2018 after selling out during the quarter.
  • Trexquant Investment sold 11,275 Clementia Pharmaceuticals Inc. shares in Q4 2018, an estimated $126K.
  • Trexquant Investment first reported a position in Clementia Pharmaceuticals Inc. in Q3 2018 and held it in 1 quarter.
  • Trexquant Investment's Clementia Pharmaceuticals Inc. position peaked at $126K in Q3 2018.
  • 31 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q4 2018.

Based on Trexquant Investment's 13F filing for Q4 2018, filed 13 Feb 2019.